What question did this study set out to answer?

This research aims to explore how ApoE and SLCO1B1 gene polymorphisms affect the effectiveness and safety of statin therapy in patients with dyslipidemia.

March 22, 2026Pharmacogenetics and Genomics

Effects of apolipoprotein E and solute carrier organic anion transporter family member 1B1 gene polymorphisms on statin efficacy and safety in dyslipidemic patients

View Full Paper

Ask AI

Bookmark

Authors

XWXiaohong Wu YCYumei Cai YSYiji Su

Discussion

Member takes

Overview

This retrospective analysis investigates the role of specific gene variations on statin efficacy in dyslipidemic patients, indicating important genetic influences.

Key Points

This research aims to explore how ApoE and SLCO1B1 gene polymorphisms affect the effectiveness and safety of statin therapy in patients with dyslipidemia.
Retrospective analysis of dyslipidemic inpatients from April 2024 to March 2025
Genetic testing for SLCO1B1 and ApoE polymorphisms conducted
Associations between genotypes and lipid levels, as well as safety indicators, were analyzed.
E3 carriers had higher LDL cholesterol post-atorvastatin treatment compared to E2 carriers, with 2.85 ± 1.00 mmol/l vs. 2.28 ± 0.96 mmol/l (P = 0.026)
No significant association was noted between SLCO1B1 genotypes and safety outcomes like creatine kinase and alanine aminotransferase levels.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69bf89a9f665edcd009e981d https://doi.org/10.1097/fpc.0000000000000598

View Full Paper

Ask AI

Bookmark

March 22, 2026Pharmacogenetics and Genomics

Effects of apolipoprotein E and solute carrier organic anion transporter family member 1B1 gene polymorphisms on statin efficacy and safety in dyslipidemic patients

View Full Paper

Ask AI

Bookmark

Authors

XWXiaohong Wu YCYumei Cai YSYiji Su

Discussion

Member takes

Overview

This retrospective analysis investigates the role of specific gene variations on statin efficacy in dyslipidemic patients, indicating important genetic influences.

Key Points

This research aims to explore how ApoE and SLCO1B1 gene polymorphisms affect the effectiveness and safety of statin therapy in patients with dyslipidemia.
Retrospective analysis of dyslipidemic inpatients from April 2024 to March 2025
Genetic testing for SLCO1B1 and ApoE polymorphisms conducted
Associations between genotypes and lipid levels, as well as safety indicators, were analyzed.
E3 carriers had higher LDL cholesterol post-atorvastatin treatment compared to E2 carriers, with 2.85 ± 1.00 mmol/l vs. 2.28 ± 0.96 mmol/l (P = 0.026)
No significant association was noted between SLCO1B1 genotypes and safety outcomes like creatine kinase and alanine aminotransferase levels.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69bf89a9f665edcd009e981d https://doi.org/10.1097/fpc.0000000000000598

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark